PRMT1 and neoplasm: Future studies could address this by employing combination strategies, such as co‐administration of PRMT1 inhibitors with anti‐angiogenic agents (e.g., bevacizumab[50]), to induce tumor hypoxia and validate the axis in physiologically relevant contexts.